Physician profile
Adam A Ofer
NPI 1689751695
$4,220.06
in general payments reported to CMS, 2019-2025
31 companies · $904 in 2025
The $904 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $121 · 2021: $313 · 2022: $948 · 2023: $998 · 2024: $632 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.47 | 2019-2023 | |
| Exeltis, USA INC. | $561.82 | 2019-2024 | Slynd, Tyblume |
| Mayne Pharma Commercial LLC | $397.01 | 2021-2025 | |
| Astellas Pharma US INC | $377.36 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $257.32 | 2023-2025 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $194.92 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $194.33 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $142.59 | 2023 | Acessa Provu System |
| Coloplast Corp | $142.42 | 2019-2025 | Altis |
| Myovant Sciences INC. | $116.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $112.90 | 2020-2024 | Gardasil 9, Gardasil |
| Millicent US INC | $109.86 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Pfizer INC. | $104.84 | 2021-2023 | |
| Caldera Medical, INC | $102.08 | 2022 | |
| Biogen, INC. | $87.22 | 2025 | Zurzuvae |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $71.77 | 2022-2024 | |
| Aspira Women'S Health INC | $71.23 | 2019-2025 | Ova1 |
| Organon LLC | $64.78 | 2022-2025 | Nexplanon |
| Allergan, INC. | $56.37 | 2019-2020 | |
| Novo Nordisk INC | $52.50 | 2025 | Wegovy |
| Agile Therapeutics, INC. | $48.83 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $47.97 | 2021-2022 | |
| Axonics, INC. | $41.01 | 2023-2024 | Axonics |
| Evofem Biosciences, INC. | $39.92 | 2022 | |
| Coopersurgical, INC. | $38.66 | 2024 | Paragard T 380a |
| Medicem INC. | $34.26 | 2020-2022 | |
| Avion Pharmaceuticals | $32.65 | 2021-2022 | |
| Duchesnay USA Incorporated | $22.00 | 2019 | |
| Shield Therapeutics INC | $21.48 | 2024 | |
| Covidien LP | $12.79 | 2019 | |
| Clovis Oncology, INC. | $7.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Ofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.